Celldex Therapeutics Inc

Celldex Raises $345 Million in Public Offering to Fund Next‑Generation Biotherapeutics

Celldex Therapeutics closes $345 M public offering, raising capital to accelerate its immunology‑focused pipeline while adding 11.9 M shares and 1.55 M option shares.

06/04/2026, 17:20

2 minutes to read

Celldex Therapeutics’ Barzolvolimab Shows Promising Results in Angioedema Treatment, Boosting Share Prices

Celldex Therapeutics Inc. has reported promising clinical trial results for its drug barzolvolimab, showing significant efficacy in treating angioedema associated with chronic spontaneous urticaria.

16/06/2025, 02:46

3 minutes to read

Celldex Therapeutics’ Barzolvolimab Shows Promise in CSU Treatment, Boosting Investor Confidence

Celldex Therapeutics Inc. is poised for significant growth after presenting promising results from its Phase 2 study of barzolvolimab, a potential treatment for chronic spontaneous urticaria.

13/06/2025, 16:19

3 minutes to read

Celldex Therapeutics Leads Biopharmaceutical Innovation with Promising Immunological Therapies

Celldex Therapeutics Inc. is a leading biopharmaceutical company making significant strides in immunological applications, with a strong pipeline of potential therapies and a commitment to addressing unmet medical needs.

06/06/2025, 14:22

2 minutes to read

Celldex Therapeutics: Leading the Charge in Immunotherapy Innovation

Celldex Therapeutics Inc. is a pioneering biotech company harnessing immunology to develop groundbreaking therapies for a range of diseases, with a promising pipeline and a commitment to innovation in the face of industry challenges.

08/05/2025, 22:10

3 minutes to read